Ozempic does not slow Alzheimer's, study finds
21 hours ago
- #Novo Nordisk
- #Alzheimer’s
- #Ozempic
- Ozempic does not slow Alzheimer’s progression, as confirmed by a two-year study by Novo Nordisk.
- The drug reduces body weight by an average of 15% in obese patients and was initially thought to slow brain conditions, cancer, heart disease, liver, and kidney problems.
- It remains unclear whether these effects are due to weight loss or other health-conscious behaviors of patients taking Ozempic.
- Recent findings temper earlier excitement, as Ozempic also failed to slow neurodegeneration in Parkinson’s patients.
- However, the drug’s positive impact on cardiovascular and kidney problems appears more reliable.
- Novo Nordisk’s shares dropped 6% following the announcement.